Trially has raised $4.7m in a seed funding round and introduced its agentic AI solution, Margo, designed to increase study ...

Karyopharm Therapeutics has reached a significant milestone by completing patient enrolment for its Phase III SENTRY trial.

Amidst significant shifts in the pharmaceutical industry, the number of clinical trials has surged over the first half of ...

On this episode, the healthcare editorial team unpicks several key trials and trends from this year’s event, held from 29 ...

REDCap Cloud (nPhase) has introduced a new platform to unify real-world evidence with clinical study data within a single system.

PhaseV has entered into a strategic partnership with Bioforum to enhance the efficiency of clinical trials using advanced ...

Revolution will now explore daraxonrasib’s potential as a monotherapy and in combination with chemotherapy in late-stage PDAC trials.

Suzhou is at the heart of China’s growing biotech ecosystem and its push for global clinical trial integration. Image credit: JaCZhou/Getty Images Driven by regulatory reforms that are accelerating ...

Nektar Therapeutics has presented data of its atopic dermatitis (AD) candidate rezpeg (rezpegaldesleukin), which sent the company’s stock flying. In the RESOLVE-AD trial (NCT06136741), the mean ...

AstraZeneca obtained the global rights to Saphnelo via an exclusive licensing and partnership agreement with Medarex in 2004. Credit: Grand Warszawski / Shutterstock.com. AstraZeneca’s fully human ...

Johnson & Johnson (J&J) and Protagonist Therapeutics’ icotrokinra has outperformed BMS’s Sotyktu (deucravacitinib) in treating patients with moderate-to-severe plaque psoriasis. In the Phase III ...

AstraZeneca’s Tagrisso gained approval as a single agent for use in over 120 countries. Credit: Joe McNeela/Shutterstock.com. AstraZeneca’s Tagrisso (osimertinib), in combination with pemetrexed and ...